Citations

Showing 10 of 108094 citations.

Upregulation of Endothelin-1 May Predict Chemotherapy-Induced Cardiotoxicity in Women with Breast Cancer
Krishnarao, Krithika , Bruno, Katelyn A. , Florio, Damian N. Di , Edenfield, Brandy , Whelan, Emily R. , Macomb, Logan P. , McGuire, Molly M., Hill, Anneliese R., Ray, Jordan , Cornell, Lauren , Tan, Winston , Geiger, Xochiquetzal J., Salomon, Gary R., Douglass, Erika J. , Fairweather, DeLisa , Yamani, Mohamad H. , Watkins, Molly M. , Di Florio, Damian N, Edenfield, Brandy H, Fairweather, DeLisa , Yamani, Mohamad H , Bruno, Katelyn A , Di Florio, Damian N , McGuire, Molly M., Cornell, Lauren F

Mayo Clinic

Journal of Clinical Medicine | June 21, 2022 | Volume: 11 | Issue: 12 | Pages: 3547

10.3390/jcm11123547 | PMID 35743613 Get It

As survival in breast cancer patients from newer therapies increases, concerns for chemotherapy-induced cardiotoxicity (CIC) have offset some of these benefits, manifesting as a decline in left ventricular ejection fraction (LVEF). Patients receiving anthracycline-based chemotherapy followed by trastuzumab are at risk for CIC. Previous research evaluating whether clinical biomarkers predict cardiotoxicity has been inconsistent. Recently, angiotensin II type 1 receptor (ATR1) and endothelin 1 (ET1) have been shown to play a role in breast tumor growth. We evaluated ATR1 and ET1 expression in breast cancer tissue and its association with CIC. A total of 33 paraffin-embedded breast tissue specimens from women with breast cancer treated with anthracycline-based chemotherapy and trastuzumab were analyzed by immunohistochemistry (IHC) and qRT-PCR. We found that ET1 expression was increased in patients with an LVEF ≤ 50% (p = 0.032) with a lower LVEF correlating with higher ET1 expression (r = 0.377, p = 0.031). In patients with a change in LVEF of greater than 10%, greater ET1 expression was noted compared to those without a change in LVEF (p = 0.017). Increased ET1 expression in breast tumor tissue is associated with reduced LVEF. Future studies need to examine whether ET1 may be a tissue biomarker that helps predict the risk of developing CIC in women with breast cancer.
Uncoupling of Proliferative Capacity from Developmental Stage During Directed Cardiac Differentiation of Pluripotent Stem Cells
Minter-Dykhouse, Katherine, Folmes, Clifford D.L. , Folmes, Clifford D L , Minter‐Dykhouse, Katherine, Nelson, Timothy J.

Mayo Clinic

Stem Cells and Development | June 21, 2022 | Volume: 31 | Issue: 17-18 | Pages: 521-528

10.1089/scd.2022.0041 | PMID 35726436 Get It

Home Sweet Home: The Integrated Plastic Surgery Residency Match during the COVID-19 Pandemic
Rode, Matthew M. , Muro-Cardenas, Jose , Xie, Katherine , Weissler, Jason M., Bakri, Karim , Rode, Matthew, Weissler, Jason, Rode, Matthew , Antezana, Luis A. , Bakri, Karim

Mayo Clinic

Plastic & Reconstructive Surgery | June 20, 2022 | Volume: 150 | Issue: 2 | Pages: 492e-494e

10.1097/prs.0000000000009288 | PMID 35724416 Get It

Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design
Raoof, Mustafa , Frankel, Paul , Lim, Dean, Paz, I. Benjamin , Thomas, Rebecca, Chang, Sue , Eng, Melissa , Whelan, Richard L. , DePeralta, Danielle K. , Reymond, Marc A. , Jones, Jeremy , Merchea, Amit , Dellinger, Thanh H , Jones, Jeremy C , Sullivan, Kevin M. , Fakih, Marwan , Synold, Timothy Walter , Woo, Yanghee , Fong, Yuman , Tinsley, Raechelle

Mayo Clinic

Pleura and Peritoneum | June 20, 2022 | Volume: 7 | Issue: 4 | Pages: 169-177

10.1515/pp-2022-0116 | PMID 36560966 Get It

Abstract Objectives Peritoneal metastasis (PM) from appendiceal cancer or colorectal cancer (CRC) has significant morbidity and limited survival. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a minimally invasive approach to treat PM. We aim to conduct a dose-escalation trial of mitomycin C (MMC)-PIPAC combined with systemic chemotherapy (FOLFIRI) in patients with PM from appendiceal cancer or CRC. Methods This is a multicenter Phase I study of MMC-PIPAC (NCT04329494). Inclusion criteria include treatment with at least 4 months of first- or second-line systemic chemotherapy with ineligibility for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Exclusion criteria are: progression on chemotherapy; extraperitoneal metastases; systemic chemotherapy intolerance; bowel obstruction; or poor performance status (ECOG>2). Escalating MMC-PIPAC doses (7–25 mg/m 2 ) will be administered in combination with standard dose systemic FOLFIRI. Safety evaluation will be performed on 15 patients (dose escalation) and six expansion patients: 21 evaluable patients total. Results The primary endpoints are recommended MMC dose and safety of MMC-PIPAC with FOLFIRI. Secondary endpoints are assessment of response (by peritoneal regression grade score; Response Evaluation Criteria in Solid Tumors [RECIST 1.1], and peritoneal carcinomatosis index), progression free survival, overall survival, technical failure rate, surgical complications, conversion to curative-intent CRS-HIPEC, patient-reported outcomes, and functional status. Longitudinal blood and tissue specimens will be collected for translational correlatives including pharmacokinetics, circulating biomarkers, immune profiling, and single-cell transcriptomics. Conclusions This Phase I trial will establish the recommended dose of MMC-PIPAC in combination with FOLFIRI. Additionally, we expect to detect an early efficacy signal for further development of this therapeutic combination.
Delayed recurrence of pediatric arteriovenous malformations after radiologically confirmed obliteration
Oushy, Soliman , Gilder, Hannah E., Pollock, Bruce E. , Ahn, Edward S. , Oushy, Soliman H , Nesvick, Cody L. , Lanzino, Giuseppe , Daniels, David J.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | June 20, 2022 | Volume: 30 | Issue: 2 | Pages: 195-202

10.3171/2022.4.peds21471 | PMID 35623369 Get It

OBJECTIVE Arteriovenous malformations (AVMs) are a major cause of intracerebral hemorrhage in children, resulting in significant morbidity and mortality. Moreover, the rate of AVM recurrence in children is significantly higher than in adults. The aim of this study was to define the risk of delayed pediatric AVM (pAVM) recurrence following confirmed radiological obliteration. Further understanding of this risk could inform the role of long-term radiological surveillance. METHODS The authors conducted a retrospective review of ruptured and unruptured pAVM cases treated at a single tertiary care referral center between 1994 and 2019. Demographics, clinical characteristics, treatment modalities, and AVM recurrence were analyzed. RESULTS A total of 102 pediatric patients with intracranial AVMs, including 52 (51%) ruptured cases, were identified. The mean patient age at presentation was 11.2 ± 4.4 years, and 51 (50%) patients were female. The mean nidus size was 2.66 ± 1.44 cm. The most common Spetzler-Martin grades were III (32%) and II (31%). Stereotactic radiosurgery was performed in 69.6% of patients. AVM obliteration was radiologically confirmed in 68 (72.3%) of 94 patients with follow-up imaging, on angiography in 50 (73.5%) patients and on magnetic resonance imaging in 18 (26.5%). AVM recurrence was identified in 1 (2.3%) of 43 patients with long-term surveillance imaging over a mean follow-up of 54.7 ± 38.9 months (range 2–153 months). This recurrence was identified in a boy who had presented with a ruptured AVM and had been surgically treated at 5 years of age. The AVM recurred 54 months after confirmed obliteration on surveillance digital subtraction angiography. Two other cases of presumed AVM recurrence following resection in young children were excluded from recurrence analysis because of incomplete sets of imaging available for review. CONCLUSIONS AVM recurrence following confirmed obliteration on imaging is a rare phenomenon, though it occurs more frequently in the pediatric population. Regular long-term follow-up with dedicated surveillance angiography is recommended even after obliteration following resection.
Management and Outcomes of Severe Hypoglycemia Treated by Emergency Medical Services in the U.S. Upper Midwest
Swanson, Kristi M. , Glasgow, Amy E. , McCoy, Rozalina G. , Myers, Lucas A. , McCoy, Rozalina Grubina

Mayo Clinic

Diabetes Care | June 20, 2022 | Volume: 45 | Issue: 8 | Pages: 1788-1798

10.2337/dc21-1811 | PMID 35724305 Get It

OBJECTIVE To examine factors associated with emergency department (ED) transport after hypoglycemia treated by emergency medical services (EMS) and assess the impact of ED transport on severe hypoglycemia recurrence. RESEARCH DESIGN AND METHODS We retrospectively analyzed electronic health records of a multistate advanced life support EMS provider and an integrated healthcare delivery system serving an overlapping geographic area in the upper Midwest. For adults with diabetes treated by EMS for hypoglycemia between 2013 and 2019, we examined rates of ED transport, factors associated with it, and its impact on rates of recurrent hypoglycemia requiring EMS, ED, or hospital care within 3, 7, and 30 days. RESULTS We identified 1,977 hypoglycemia-related EMS encounters among 1,028 adults with diabetes (mean age 63.5 years [SD 17.7], 55.2% male, 87.4% non-Hispanic White, 42.4% rural residents, and 25.6% with type 1 diabetes), of which 46.4% resulted in ED transport (31.1% of calls by patients with type 1 diabetes and 58.0% of calls by patients with type 2 diabetes). Odds of ED transport were lower in patients with type 1 diabetes (odds ratio [OR] 0.44 [95% CI 0.31–0.62] vs. type 2 diabetes) and higher in patients with prior ED visits (OR 1.38 [95% CI 1.03–1.85]). Within 3, 7, and 30 days, transported patients experienced recurrent severe hypoglycemia 2.8, 5.2, and 10.6% of the time, respectively, compared with 7.4, 11.2, and 22.8% of the time among nontransported patients (all P < 0.001). This corresponds to OR 0.58 (95% CI 0.42–0.80) for recurrent severe hypoglycemia within 30 days for transported versus nontransported patients. When subset by diabetes type, odds of recurrent severe hypoglycemia among transported patients were 0.64 (95% CI 0.43–0.96) and 0.42 (95% CI 0.24–0.75) in type 1 and type 2 diabetes, respectively. CONCLUSIONS Transported patients experienced recurrent hypoglycemia requiring medical attention approximately half as often as nontransported patients, reinforcing the importance of engaging patients in follow-up to prevent recurrent events.
A rare case of recurrent group A streptococcal vulvovaginitis in a premenopausal woman
Ederaine, Sophia A. , Torgerson, Rochelle R. , Marnach, Mary L.

Mayo Clinic

International Journal of Women’s Dermatology | June 20, 2022 | Volume: 8 | Issue: 2 | Pages: e022

10.1097/jw9.0000000000000022 | PMID 35647255 Get It

Repair of Preauricular and Upper Helical Defects With Exposed Cartilage
Campbell, Elliott H. , Mohandesi, Nessa Aghazadeh, Baum, Christian L. , Demer, Addison M. , Aghazadeh, Nessa , Aghazadeh Mohandesi, Nessa

Mayo Clinic

Dermatologic Surgery | June 20, 2022 | Volume: 49 | Issue: 2 | Pages: 181-183

10.1097/dss.0000000000003513 | PMID 36728069 Get It

Immunohistochemistry Use in Mohs Micrographic Surgery: A Survey of the American College of Mohs Surgery
Kobic, Ajdin, Demer, Addison M. , Vidal, Nahid Y. , Demer, Addison, Sutton, Elizabeth

Mayo Clinic

Dermatologic Surgery | June 20, 2022 | Volume: 48 | Issue: 8 | Pages: 893-894

10.1097/dss.0000000000003512 | PMID 35917273 Get It

Risk Factors for Canalicular Injury After Mohs Micrographic Surgery
Campbell, Elliott H. , Leon, Daniel E. Sotelo, Baum, Christian L. , Wagner, Lilly H. , Sotelo Leon, Daniel E

Mayo Clinic

Dermatologic Surgery | June 20, 2022 | Volume: 48 | Issue: 9 | Pages: 912-915

10.1097/dss.0000000000003509 | PMID 36054042 Get It

BACKGROUND There is a paucity of literature describing risk factors for canalicular injury (CI) during periocular Mohs micrographic surgery (Mohs). OBJECTIVE This study aimed to determine factors associated with CI after Mohs. This information may inform patient counseling and surgical planning. MATERIALS AND METHODS This case–control study compared subjects with canalicular injury after Mohs with subjects requiring ophthalmologic Mohs repair without canalicular injury. All subjects who had CI after Mohs were included in the control group. CI from other causes were excluded. RESULTS Basal cell carcinoma was the most common etiologic tumor (p < .00001). Canalicular injury was associated with infiltrative, morpheaform, and/or micronodular-type basal cell carcinoma. Initial tumor location involving the medial canthus was not statistically different between cases and controls (32% vs 17%, p = .22). Having a final defect involving the medial canthus region was more likely in cases versus controls (55% vs 26%, p = .01952). CONCLUSION Although most final defects involved the medial canthal region, a substantial number of tumors resulting in CI did not initially seem to involve the medial canthus. Surgeons cannot rely simply on anatomical location when assessing risk for CI, and anticipation of need for canalicular reconstruction is challenging.